NEW YORK, March 29 – MiraiBio and BioSource International said Thursday they have agreed to jointly develop biological assays for use in drug discovery using Luminex’s LabMAP technology.

BioSource, based in Camarillo, Calif., will develop assay panels related to extracellular signaling, signal transduction, and cytokine research, while MiraiBio, formerly the Genetic Systems Division of Hitachi Software Engineering, will write software to accompany the assays.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.